Acasti Pharma reported $20M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Acasti Pharma USD 20M 8.94M Jun/2025
Addus HomeCare 91.18M 5.78M Jun/2025
Amarin USD 119.52M 1.51M Mar/2025
Cassava Sciences USD 112.38M 16.19M Jun/2025
Knight Therapeutics CAD 5.81M 3.59M Sep/2024
Option Care Health USD 198.82M 27.45M Jun/2025
Organigram Holdings 35.88M 8.42M Jun/2025
Tilray USD 189.7M 15.49M Nov/2024